AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28920756 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 27229736 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (n=26): twice weekly 60-min group exercise classes, at least 3 days/week self-directed exercise, daily pedometer, weekly telephone counseling
Number of subjects: 51
Study 27229736 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (n=25)
Number of subjects: 51
Study 26403206 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound-guided femoral nerve block (FNB) with 20 mL of 0.5% bupivacaine
Number of subjects: 50
Study 26403206 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 50
Study 26403206 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound-guided femoral nerve block (FNB)
Number of subjects: 50
Study 23901023 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG-rich green tea extract (300-900 mg/day)
Number of subjects: 0
Study 20948453 — intervention group
Group type: EXPERIMENTAL
Intervention: HibMenCY‐TT
Number of subjects: 1104
Study 18303408 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant platinum/taxanes chemotherapy
Number of subjects: 22
Study 18303408 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (radical hystero-oophorectomy, omentectomy, lymphadenectomy)
Number of subjects: 22
Study 18303408 — intervention group
Group type: EXPERIMENTAL
Intervention: FPDNA levels above cutoff after chemotherapy
Number of subjects: 22
Study 18303408 — intervention group
Group type: EXPERIMENTAL
Intervention: FPDNA levels below cutoff after chemotherapy
Number of subjects: 22
Study 18303408 — intervention group
Group type: EXPERIMENTAL
Intervention: FPDNA levels above and below cutoff
Number of subjects: 22
Study 18303408 — intervention group
Group type: COMPARATOR
Intervention: Healthy blood donor volunteers
Number of subjects: 22
Study 16569962 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium membrane with autologous bone graft (test group)
Number of subjects: 10
Study 16569962 — intervention group
Group type: COMPARATOR
Intervention: Titanium membrane without autologous bone graft (control group)
Number of subjects: 10
Study 15189588 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally instilled folk theories (Asian-primed)
Number of subjects: 0
Study 15189588 — intervention group
Group type: COMPARATOR
Intervention: Culturally instilled folk theories (American-primed)
Number of subjects: 0
Study 10961518 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral montelukast
Number of subjects: 14
Study 10961518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9174478 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake of 684 mg/d (baseline)
Number of subjects: 14
Study 9174478 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced calcium intake (280 mg/d)
Number of subjects: 14
Study 9174478 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased calcium intake (1281 mg/d)
Number of subjects: 14
Study 9174478 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline calcium intake)
Number of subjects: 14
Study 7721145 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to chemical disinfectants
Number of subjects: 0
Study 7721145 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygienic prophylactic recommendations
Number of subjects: 0
Study 2595747 — intervention group
Group type: EXPERIMENTAL
Intervention: Terodiline (25 mg b.i.d.)
Number of subjects: 23
Study 2595747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10940 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimiterol (0.5 mug kg‐1 min‐1)
Number of subjects: 7
Study 10940 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimiterol (0.05 mug kg‐1 min‐1)
Number of subjects: 7
Study 10940 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (0.3 mug kg‐1 min‐1)
Number of subjects: 7
Study 10940 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (0.03 mug kg‐1 min‐1)
Number of subjects: 7
Study 10940 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (0.05 mug kg‐1 min‐1)
Number of subjects: 7
Study 10940 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (0.005 mug kg‐1 min‐1)
Number of subjects: 7
Study 10940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31427252 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (45 mg/kg per day)
Number of subjects: 252
Study 31427252 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (5 mg/kg per day)
Number of subjects: 252
Study 31427252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 28624576 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid
Number of subjects: 113
Study 28624576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 25933358 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg/day
Number of subjects: 1308
Study 25933358 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 1308
Study 25933358 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 600 mg/day
Number of subjects: 1308
Study 25933358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1308
Study 25024070 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 3.6 mg/kg every 3 weeks
Number of subjects: 884
Study 22967970 — intervention group
Group type: EXPERIMENTAL
Intervention: salvia miltiorrhiza and ligustrazine injection (250 mL glucose injection containing 10 mL concoction, once a day for three days)
Number of subjects: 20
Study 22967970 — intervention group
Group type: COMPARATOR
Intervention: routine treatment methods (fluid resuscitation, anti‐infection treatment, support treatment, organ‐protection treatment)
Number of subjects: 20
Study 19533762 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-gastric violet light phototherapy
Number of subjects: 18
Study 19533762 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard antibiotic treatment)
Number of subjects: 18
Study 17696983 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ultrasound training
Number of subjects: 0
Study 17696983 — intervention group
Group type: COMPARATOR
Intervention: Delayed ultrasound training (wait-list control)
Number of subjects: 0
Study 17696983 — intervention group
Group type: COMPARATOR
Intervention: Standard instruction on abdominal examination
Number of subjects: 0
Study 15611509 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m² intravenously over 30 minutes on days 1 and 8 and ISIS‐2503 6 mg/kg/d as a continuous intravenous infusion over 14 days of an every‐3‐weeks cycle
Number of subjects: 48
Study 15611509 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and ISIS‐2503 combination
Number of subjects: 48
Study 11972979 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined high-dose hepatitis A and B vaccine (0, 6 month schedule)
Number of subjects: 100
Study 11972979 — intervention group
Group type: COMPARATOR
Intervention: Twinrix (0, 1, 6 month schedule)
Number of subjects: 100
Study 9831104 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative endoscopic submucosal injection of CH-40 (group A)
Number of subjects: 45
Study 9831104 — intervention group
Group type: COMPARATOR
Intervention: No staining (group B)
Number of subjects: 45
Study 8744963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact word pairs
Number of subjects: 0
Study 8744963 — intervention group
Group type: COMPARATOR
Intervention: Recombined word pairs
Number of subjects: 0
Study 8744963 — intervention group
Group type: EXPERIMENTAL
Intervention: Speeded relatedness judgment task
Number of subjects: 0
Study 8744963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-modal presentation
Number of subjects: 0
Study 8744963 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit speeded recognition task
Number of subjects: 0
Study 1693173 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine pranobex (1 g three times a day)
Number of subjects: 866
Study 1693173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 866
Study 1693173 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine pranobex
Number of subjects: 866
Study 6104083 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg trimethoprim
Number of subjects: 279
Study 6104083 — intervention group
Group type: COMPARATOR
Intervention: 100 mg trimethoprim combined with 500 mg sulphamethoxazole (co-trimoxazole)
Number of subjects: 279
Study 30517888 — intervention group
Group type: EXPERIMENTAL
Intervention: weWomen intervention (culturally tailored for immigrant and refugee women)
Number of subjects: 1250
Study 30517888 — intervention group
Group type: EXPERIMENTAL
Intervention: ourCircle intervention (culturally tailored for indigenous women)
Number of subjects: 1250
Study 30517888 — intervention group
Group type: COMPARATOR
Intervention: usual safety planning control website
Number of subjects: 1250
Study 29165775 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute re-operation predictive index-intra-abdominal pressure (ARPI-IAP) model
Number of subjects: 300
Study 29165775 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models developed in estimation group
Number of subjects: 300
Study 29165775 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of the ARPI-IAP model
Number of subjects: 300
Study 25801761 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxentan (endothelin A antagonist)
Number of subjects: 27
Study 25801761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 25801761 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 27
Study 23480506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intensive educational programme
Number of subjects: 80
Study 23480506 — intervention group
Group type: COMPARATOR
Intervention: Routine guidance (Control)
Number of subjects: 80
Study 21385192 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg b.d. for 12 months
Number of subjects: 77
Study 21385192 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg b.d. for 12 months
Number of subjects: 77
Study 19109804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to promote breast cancer screening
Number of subjects: 0
Study 16567151 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisolid yogurt (378 g)
Number of subjects: 32
Study 16567151 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid yogurt (378 g)
Number of subjects: 32
Study 16567151 — intervention group
Group type: COMPARATOR
Intervention: Peach-flavored dairy beverage (400 mL)
Number of subjects: 32
Study 16567151 — intervention group
Group type: COMPARATOR
Intervention: Peach juice beverage (400 mL)
Number of subjects: 32
Study 12735507 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study 12735507 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy
Number of subjects: 0
Study 10717010 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg twice daily for 16 weeks)
Number of subjects: 55
Study 10717010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 10717010 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg per day for 16 weeks, open-label phase)
Number of subjects: 55
Study 2062329 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms of inhaled budesonide twice a day
Number of subjects: 103
Study 2062329 — intervention group
Group type: COMPARATOR
Intervention: 375 micrograms of inhaled terbutaline twice a day
Number of subjects: 103
Study 6314720 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid (Vicryl)
Number of subjects: 306
Study 6314720 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin 910 (Dexon)
Number of subjects: 306
Study 31476447 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive outcomes presented to participants in the intervention group (n = 48)
Number of subjects: 98
Study 31476447 — intervention group
Group type: COMPARATOR
Intervention: Neutral outcomes presented to the control group (n = 50)
Number of subjects: 98
Study 31476447 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipation of positive outcomes
Number of subjects: 98
Study 29964041 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic supplement (2.8 g/d Bimuno containing 1.37 g beta-galactooligosaccharide) plus placebo (Mediterranean-type diet)
Number of subjects: 40
Study 29964041 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement (2.8 g xylose) plus low-FODMAP diet
Number of subjects: 40
Study 26043651 — intervention group
Group type: EXPERIMENTAL
Intervention: High insertion torque (≥50 Ncm)
Number of subjects: 116
Study 26043651 — intervention group
Group type: COMPARATOR
Intervention: Regular insertion torque (<50 Ncm)
Number of subjects: 116
Study 24918721 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical policresulen + cinchocaine
Number of subjects: 43
Study 24918721 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 43
Study 24918721 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual guidelines with oral medications)
Number of subjects: 43
Study 22789662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 38
Study 22789662 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 38
Study 19660392 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 214
Study 19660392 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 214
Study 19660392 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic tests (exercise treadmill test, exercise thallium scintigraphy, coronary computed tomography)
Number of subjects: 214
Study 19660392 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of patients undergoing coronary revascularization
Number of subjects: 214
Study 18241645 — intervention group
Group type: EXPERIMENTAL
Intervention: Danning Tablet (DNT)
Number of subjects: 135
Study 18241645 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 135
Study 16048421 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training group
Number of subjects: 33
Study 16048421 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training group
Number of subjects: 33
Study 16048421 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 16048421 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33
Study 12209517 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IV CYC (500 mg, 6 fortnightly pulses) followed by AZA
Number of subjects: 90
Study 12209517 — intervention group
Group type: COMPARATOR
Intervention: High-dose IV CYC (6 monthly pulses and 2 quarterly pulses, doses increased according to WBC count) followed by AZA
Number of subjects: 90
Study 10828561 — intervention group
Group type: EXPERIMENTAL
Intervention: Novoste Beta‐Cath System with 90Sr/Y
Number of subjects: 42
Study 10828561 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidant Intimal Hyperplasia Inhibition with Beta In‐stent Trial (INHIBIT) using 32P
Number of subjects: 42
Study 8955439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (65 mg/kg/day, adjusted as needed)
Number of subjects: 35
Study 8955439 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (6.5 mg/kg/day) or Fentanyl (65 micrograms/kg/day)
Number of subjects: 35
Study 2392914 — intervention group
Group type: EXPERIMENTAL
Intervention: 15‐propionat‐PGF2 alpha‐isopropylester (15‐prop‐PGF2 alpha‐IE)
Number of subjects: 12
Study 2392914 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF2 alpha‐isopropylester (PGF2 alpha‐IE)
Number of subjects: 12
Study 2392914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6508006 — intervention group
Group type: EXPERIMENTAL
Intervention: 2IRZ/4I2R2
Number of subjects: 213
Study 6508006 — intervention group
Group type: COMPARATOR
Intervention: 2IRSZ/4I2R2
Number of subjects: 213
Study 30709605 — intervention group
Group type: EXPERIMENTAL
Intervention: iTClamp
Number of subjects: 1
Study 30709605 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Catheter Tamponade (BCT)
Number of subjects: 1
Study 30709605 — intervention group
Group type: COMPARATOR
Intervention: Direct Manual Pressure (DMP)
Number of subjects: 1
Study 30203775 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin eye drops
Number of subjects: 0
Study 30203775 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin eye drops
Number of subjects: 0
Study 27009149 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma-tailored pulmonary rehabilitation
Number of subjects: 30
Study 27009149 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 25063793 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg once daily)
Number of subjects: 36
Study 25063793 — intervention group
Group type: COMPARATOR
Intervention: GTN (0.6 mg/h, 2 h/day)
Number of subjects: 36
Study 25063793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23223178 — intervention group
Group type: EXPERIMENTAL
Intervention: bucindolol
Number of subjects: 303
Study 20068373 — intervention group
Group type: EXPERIMENTAL
Intervention: Farmers
Number of subjects: 392
Study 20068373 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 392
Study 17999973 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 121
Study 17999973 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 121
Study 16869933 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin
Number of subjects: 508
Study 14663405 — intervention group
Group type: EXPERIMENTAL
Intervention: IPOM (Gore‐Tex DualMesh Plus biomaterial with holes Corduroy)
Number of subjects: 50
Study 14663405 — intervention group
Group type: COMPARATOR
Intervention: Open tension free (patch and plug technique with Marlex prosthesis)
Number of subjects: 50
Study 14663405 — intervention group
Group type: EXPERIMENTAL
Intervention: IPOM
Number of subjects: 50
Study 14663405 — intervention group
Group type: COMPARATOR
Intervention: Open tension free
Number of subjects: 50
Study 14663405 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 10651696 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer-assisted learning (CAL)
Number of subjects: 227
Study 10651696 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-interactive computer-assisted learning (CAL)
Number of subjects: 227
Study 10651696 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 227
Study 8889412 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (50 micrograms delivered as a bolus via an infusion pump) in 10 degrees C water condition
Number of subjects: 10
Study 8889412 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (50 micrograms delivered as a bolus via an infusion pump) in 2 degrees C water condition
Number of subjects: 10
Study 8889412 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (50 micrograms delivered as a bolus via an infusion pump) in 37 degrees C water condition
Number of subjects: 10
Study 8889412 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective effects of fentanyl
Number of subjects: 10
Study 2053453 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg of elemental calcium supplementation
Number of subjects: 19
Study 2053453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6313594 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (5 mg/kg)
Number of subjects: 59
Study 6313594 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (oral)
Number of subjects: 59
Study 6313594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 30723975 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended haemodialysis hours (median 24 h/week)
Number of subjects: 54
Study 30723975 — intervention group
Group type: COMPARATOR
Intervention: Standard haemodialysis hours (median 12 h/week)
Number of subjects: 54
Study 30723975 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers
Number of subjects: 54
Study 28742609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contract-relax stretching (DS)
Number of subjects: 48
Study 28742609 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SS)
Number of subjects: 48
Study 28742609 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study 26930571 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART initiation (early group)
Number of subjects: 816
Study 26930571 — intervention group
Group type: COMPARATOR
Intervention: Delayed ART initiation (delayed group)
Number of subjects: 816
Study 24930168 — intervention group
Group type: EXPERIMENTAL
Intervention: Late verbal task
Number of subjects: 0
Study 24930168 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous verbal task
Number of subjects: 0
Study 24930168 — intervention group
Group type: COMPARATOR
Intervention: No verbal task
Number of subjects: 0
Study 24930168 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive radio task
Number of subjects: 0
Study 21637192 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-up ventilation rate of 30 min(‐1)
Number of subjects: 26
Study 21637192 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-up ventilation rate of 40 min(‐1)
Number of subjects: 26
Study 21637192 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-up ventilation rate of 50 min(‐1)
Number of subjects: 26
Study 21637192 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-up ventilation rates of 30, 40, and 50 min(‐1)
Number of subjects: 26
Study 20705381 — intervention group
Group type: EXPERIMENTAL
Intervention: Transumbilical port
Number of subjects: 50
Study 17653075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 68
Study 15896247 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine alone
Number of subjects: 8